// App-Quantinova.ai

: LONG-TERM INHIBITION OF CHK1/CHK2 KINASES MODIFY ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINE RESPONSE TO DNA DAMAGING AGENTS

Researchers

Presenter

  • Andrea Ghelli Luserna Di Rora'

Principal Investigators

  • Matteo Bocconcelli

  • Antonella Padella

  • Maria Chiara Fontana

  • Anna Ferrari

  • Enrica Imbrogno

  • Carmen Baldazzi

  • Nicoletta Testoni

  • Giorgia Simonetti

  • Giovanni Martinelli

Medical Centers

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • )Department of Experimental, Diagnostic and Specialty Medicine - DIMES, Institute of Hematology "L. and A. Seràgnoli", Bologna, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Checkpoint kinase 1

  • checkpoint kinase 2

Drug/Treatment

  • Methotrexate

  • Clofarabine

  • Doxorubicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved